logo

ARQT

ArcutisยทNASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --

ARQT Profile

Arcutis Biotherapeutics, Inc.

A late-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology

Biological Technology
--
01/31/2020
NASDAQ Stock Exchange
342
12-31
Common stock
3027 Townsgate Road Suite 300, Westlake Village, California 91361
--
Arcutis Biotherapeutics, Inc., formerly known as Arcutis, Inc., was established in June 2016 under the laws of the State of Delaware and later changed its name to Arcutis Biotherapeutics, Inc. The company is a late-stage biopharmaceutical company dedicated to the development and commercialization of treatments for skin diseases with unmet medical needs. The company's current product portfolio includes topical treatments with the potential to address immune-mediated skin diseases and diseases or immune skin diseases. The company's strategy is to identify and develop therapies against proven biological targets in dermatology to provide differentiated clinical features that address the major shortcomings of existing therapies in terms of target indications.